Abstract
<h3>To the Editor:—</h3> Your editorial on aurotherapy in rheumatoid arthritis (The Journal, August 2, p. 368) does not seem to me a fair statement of the present status of gold therapy either in this country or in England. At the last meeting of the American Rheumatism Association an entire morning was devoted to this subject. I believe the majority of the members of that association now agree that gold therapy is the treatment of choice for atrophic arthritis and think that it is especially valuable in early cases. As far as my associates and I can determine, gold is the only known drug that specifically influences the course of atrophic arthritis in a favorable manner. Since our paper on this subject was written we have continued to use gold, and by reducing the weekly dosage to 0.05 Gm. of sodium gold thiomalate, which contains 50 per cent gold, we have
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
